Background
==========

The western honey bee (*Apis mellifera*) is an important insect species for the commercial pollination of high-value crops and plays a crucial role in agricultural ecology ([@ref-15]; [@ref-35]). However, as highlighted by the elevated losses of honey bee colonies in major beekeeping regions owing to colony collapse disorder, annual declines in honey bee populations have significantly increased over the past two decades ([@ref-11]). Multiple explanations for colony losses have been proposed, including habitat degradation and the effects of pathogens, parasites and pesticides ([@ref-7]; [@ref-39]). Of the numerous infectious pathogens and infesting parasites, *Varroa destructor*, an ectoparasitic mite, and deformed wing virus (DWV) are regarded as serious threats to honey bee health and survival ([@ref-5]; [@ref-32]).

DWV, often considered among the most common and prevalent viruses in honey bee colonies ([@ref-10]; [@ref-17]), was originally isolated from a sample of symptomatic honey bees during the early 1980s in Japan; currently, DWV is distributed worldwide, wherever *Varroa* mites are found ([@ref-1]). DWV infection induces clinical symptoms that include deformed and crippled wings, discoloration and paralysis and a generally shortened lifespan ([@ref-47]). DWV is a positive-strand RNA virus belong to the family *Iflaviridae* of the order *Picornavirales* ([@ref-25]). DWV is separated into three major variants: DWV-A, -B and -C ([@ref-31]). The International Committee on Taxonomy of Viruses recognizes two master variants of DWV-A---DWV and Kakugo virus---whereas DWV-B contains *Varroa destructor* viruses and DWV-C, which has only recently been described, is phylogenetically distinct from both A and B types ([@ref-17]; [@ref-31]). DWV has a single-stranded RNA genome of approximately 10,000 nucleotides and the whole genome encodes one large, uninterrupted open-reading frame that is translated into polyproteins that are cleaved by viral proteases to produce structural and nonstructural proteins ([@ref-3]). The three major structural proteins VP1, VP2 and VP3 from one polyprotein precursor form a protomer, an elementary building block of the virus capsid ([@ref-35]; [@ref-23]).

Although DWV is regarded as one of the primary viruses that are associated with honeybee colony losses ([@ref-12]), the effective medicine and method against DWV remain limited. Antibodies, as naturally occurring proteins, play an important role in neutralizing virus; thus, they have been widely utilized in the prevention and control of epidemic diseases as well as for research purposes ([@ref-18]; [@ref-33]). The capability of virus neutralization and antibodies titers primarily depends on antigenic immunogenicity. It is crucial to identify an excellent immunogenic antigen for developing therapeutic antibodies. A previous study has demonstrated that viral structural proteins not only play an important role in viral infection but also possess superior immunogenicity in producing neutralizing antibodies ([@ref-34]; [@ref-43]; [@ref-29]); we thus speculate that the three major DWV proteins have possibly been suitable targets for effective therapeutic antibody against DWV. Presently, the VP1 recombinant fragment protein of DWV has already been successfully recombinantly expressed and used for the generation of monoclonal antibodies ([@ref-24]); however, limited studies on their antigenic differences of the three structural proteins have restricted the development of therapeutic drugs.

In the present study, we obtained the recombinant proteins *roVP1*, *roVP2* and *roVP3* of DWV in *E. coli* using bioinformatics-based codon optimization; next, BALB/c mice were immunized with the recombinant proteins and the immunogenicity of the three recombinant proteins was evaluated on the basis of the specific antibody level, lymphocyte proliferation and cytokine expression. Furthermore, the challenge test was performed to assess the virus-neutralizing ability of anti-*roVP*-antisera (*roVP1* or *roVP2* or *roVP3*). To the best of our knowledge, this is the first study to express DWV structural protein genes and evaluate their immunogenic potential.

Materials and Methods
=====================

Ethics statement and animal care
--------------------------------

All animal experiments were performed in accordance with the ethical guidelines of Jinzhou Medical University and the research protocol was approved by the Animal Care and Use Committee of Jinzhou Medical University (Approval number: 2018-012). The animal facility and rearing condition was based on laboratory animal environment and facilities (GB14925-2010) and laboratory animal feed nutrient standard (GB14924.3-2010) of China. The mice were sacrificed by carbon dioxide (CO~2~) inhalation.

Strains, plasmids, virus, and antibody
--------------------------------------

*Escherichia coli* DH5α and BL21 (DE3) pLysS strains were purchased from TranGen Biotech (Beijing, China). The vector pET-28a was obtained from Novagen (San Diego, CA, USA). DWV LN8/17 strain (accession number: [MF770715](MF770715)) was isolated, identified, purified and preserved at the author's laboratory and the purification method of DWV particles was essentially described by [@ref-24]. 6\*His-tag antibody was purchased from Proteintech Group, Inc. (Wuhan, China), and horseradish peroxidase (HRP)-labeled goat anti-mouse immunoglobin G (IgG) was obtained from Bioss ANTIBODIES (Beijing, China).

Amplification and cloning
-------------------------

Using a TIAamp viral RNA kit (TIANGEN, Beijing, China), viral RNA was extracted from the purified DWV LN8/17 strain at our laboratory ([MF770715](MF770715)). Next, first-strand complementary DNA (cDNA) was transcribed using EasyScript cDNA Synthesis SuperMix (TranGen Biotech, Beijing, China), according to the manufacturer's instructions. DWV *VP1*, *VP2* and *VP3* were amplified using polymerase chain reaction (PCR) with specific primers designed based on the nucleotide sequence of the DWV LN8/17 strain (*VP1*, forward primer: 5′-ATCGTATATTAAATTTRGCAGAGG-3′, reverse primer: 5′-GGAGAGCCAGCAGAACC-3′; *VP2*, forward primer: 5′-AACAAGGACCTGGTAAGGTAAGTA-3′, reverse primer: 5′-TTATCCTAAAGTCACAAAAA-3′; VP3, forward primer: 5′-CAGTGCAGGCAAAACCAGAGATG-3′, reverse primer: 5′- CGGGACAAAATGGCGAGGAG-3′). PCR was conducted as follows: initial denaturation at 95 °C for 5 min; 25 cycles at 95 °C for 45 s and 55 °C for 40 s (*VP1*), 51 °C for 40 s (*VP2*), or 50 °C for 40 s (*VP3*); 72 °C for 60 s; and final extension for 10 min at 72 °C. The PCR products were inserted into a pMD18-T cloning vector and sequenced using Synbio Techology Corporation (Suzhou, China).

Codon optimization and construction of recombinant expression vectors
---------------------------------------------------------------------

*VP1*, *VP2* and *VP3* sequences of the DWV LN8/17 strain were analyzed and optimized based on *E. coli*-preferred codons without changing the amino acid sequence of the corresponding proteins ([@ref-14]; [@ref-30]; [@ref-42]). High-frequency-usage codons in *E. coli* were the most commonly used for each of the individual amino acids ([@ref-40]). *VP1*, *VP2* and *VP3* were subsequently reverse-translated by applying the single-most commonly used codon for each amino acid such that the final codon-optimized genes were represented by the most likely nondegenerate coding sequence and online optimization software (<http://www.jcat.de/> and <http://genomes.urv.es/OPTIMIZER/>) were utilized for codon design. The designed genes *roVP1*, *roVP2* and *roVP3* were synthesized by Synbio Techology Corporation (Suzhou, China) and inserted into the plasmid pET-28a(+) with the respective restriction enzymes (*roVP1*: BamHI and HindIII; *roVP2*: EcoRI and HindIII; and *roVP3*: BamHI and HindIII), and the 6× His tag sequence is located at the N terminus of the recombinant plasmids.

Protein expression and purification
-----------------------------------

For each protein, BL21 (DE3) pLysS cells were transformed with the appropriate recombinant plasmids and plated on LB agar with 50 μg/mL kanamycin. The transformed BL21 cells were incubated at 37 °C in an orbital shaker at 220 rpm until an OD~600~ of 0.6 was obtained and then induced with 0.1 mM, 0.25 mM, or 0.5 mM isopropyl-β-[d]{.smallcaps}-thiogalactoside (IPTG; Sigma--Aldrich, St. Louis, MO, USA) at 30 °C for 6 h. To verify the expression of the target proteins, the cells were collected by centrifugation and the target proteins were confirmed using 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).

For purifying the recombinant proteins, the cultures were harvested by centrifugation at 6,000 rpm for 30 min at 4 °C and the obtained cell pellets were stored at −80 °C for later use. All recombinant proteins in inclusion bodies were purified and collected using Ni-affinity chromatography (GE Healthsystems, Uppsala, Sweden), according to the manufacturer's instructions. Briefly, the inclusion bodies were solubilized in 6 M urea after being washed twice with a washing buffer (1,000 mL of 4 M urea, 1% Triton X-100, 5 mM EDTA, 5 mM β-mercaptoethanol and 50 mM Tris-HCl; pH 8.5) at room temperature for 30 min. The purified and denatured proteins were then refolded via dialysis in phosphate buffered saline (PBS) containing urea (initial concentration: 6 M; decreased by 1 M/dialysis) and 0.5 M arginine. The refolded proteins were then dialyzed five times against the dialysis buffer to eliminate arginine, changing from 0.5 M to 0 M buffers by the 12 h time-point. Recombinant *roVP1*, *roVP2* and *roVP3* proteins were confirmed using SDS-PAGE and Western blotting and stored at −80 °C until further use.

Western blot analysis
---------------------

The purified recombinant proteins were electrophoresed on 12% polyacrylamide slabs along with pre-stained protein markers on adjacent lanes and transferred to a polyvinylidene difluoride (PVDF) membrane. The membranes were blocked overnight with 3% (w/v) skim milk in Tris-buffered saline containing 0.05% Tween-20 (TBST) at 4 °C overnight, then incubated for 1 h at room temperature with an anti--His tag antibody (1:3,000) or an anti-DWV polyclonal antibody (1:500) in blocking buffer. The anti-DWV polyclonal antibody was obtained from the mice after they were injected thrice at biweekly intervals with the purified virus particles of DWV. Simultaneously, the serum of healthy mice was also used as the negative control for incubating with PVDF membrane of the recombinant proteins. After three washes, the membranes were incubated with HRP-labeled goat anti-mouse IgG (1:3,000) for 2 h at room temperature. After three 5 min washes with TBST, color development was performed with an ECL Western substrate (Thermo Scientific, Waltham, MA, USA).

Mice immunizations
------------------

To evaluate the immunogenicity of the recombinant proteins, 4--6 week-old female BALB/c mice (five/group) were subcutaneously immunized with a mixture of 200 µL each of the purified protein (20 µg) and 200 µL of Freund's incomplete adjuvant (Sigma). All mice were then boosted twice with the same dose of Freund's incomplete adjuvant at a 2 week interval with the same recombinant proteins. Negative controls were injected with PBS and positive controls with purified virus particles. Serum samples were prepared prior to the first immunization and 2 week after each immunization and stored at −80 °C until further analysis. At 2 week after the last inoculation, the animals were sacrificed by euthanasia to isolate splenocytes for lymphocyte proliferation in response to the recombinant proteins.

Detection of specific antibody responses using enzyme-linked immunosorbent assay
--------------------------------------------------------------------------------

According to a previously reported method, IgG levels in mice sera were detected using ELISA ([@ref-36]). In brief, microtiter plates (Corning, New York, USA) were coated with 50 μL of the purified virus particles/well at a concentration of 5 μg/mL at 4 °C overnight. The plates were washed thrice with PBS containing 0.05% TBST and blocked with 2% bovine serum albumin (BSA)--PBST for 1.5 h at 37 °C. After five washes, the sera samples (1:200) were added and the plates were incubated for 1.5 h at 37 °C. After another five washes with PBST, the plates were incubated for 1 h at 37 °C with HRP-conjugated goat anti-mice IgG (1:3,000). After a final round of washes, the products were detected by adding the developing reagent tetramethylbenzidine. Absorbance was read at a wavelength of 450 nm (OD~450~) using an ELx808 Absorbance Microplate Reader (BioTek Instruments, Winooski, VT, USA).

Lymphocyte proliferation assays and cytokine detection
------------------------------------------------------

Two weeks after the last immunization, spleens were harvested from five mice in each group under sterile conditions. Splenocyte suspensions were prepared and the splenocytes were cultured in 96-well plates at a density of 2.0 × 10^6^ cells/well in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. The cells were then stimulated with the purified virus particles (10 μg/mL) and Dulbecco's modified Eagle's medium was used alone as the negative control. According to the manufacturer's instructions, the plates were incubated in 5% CO~2~ for 24 h at 37 °C, and then a cell-counting kit 8 solution (Vazyme, Nanjing, China) was added to each well and incubated for 8 h followed by the addition of 150 μL dimethyl sulfoxide solution per well; absorbance was measured at 450 nm with a microplate reader. The stimulation index (SI) was calculated as the ratio of the OD~450~ of the stimulated cells to the OD~450~ of the negative controls. The cytokine levels of interleukin (IL)-2, IL-4, IL-10 and interferon gamma (IFN-γ) from serum samples were detected using a commercial ELISA kit (Dakewei, Cangzhou, China), according to the manufacturer's instructions.

Challenge test in the honeybee pupae
------------------------------------

For preliminarily assessing the ability of IgG antibodies from mice immunized using the recombinant proteins to neutralize DWV, we collected mice serum of the groups after the third immunization to perform the challenge test. The challenge test was modified with reference to Tehel's and Sun's methods ([@ref-38]; [@ref-39]). Prior to the challenge test, DWV were incubated with anti-*roVP1*- antisera, anti-*roVP2*-antisera, anti-*roVP3*-antisera or anti-DWV-antisera (the mice immunized with DWV viral particles and virus purification were performed as per Lamp's description ([@ref-24])) for 1 h at 37 °C. A total of 30 healthy white-eyed pupae from the same colony in Wendilou Town of Jinzhou (41.25°N, 121.11°E), were randomly distributed into six groups, with each group containing five pupae. Next, the pupae were transferred to 48-well microtiter plates, and each pupa in groups 1--4 was injected with one μL of virus particles and antisera suspension containing 1 × 10^4^ copies of DWV and 50-diluted antisera; the pupae of group 5 were only injected with a mixture of five antisera from the immunized mice and the pupae of group 6 were only injected with 1 × 10^4^ virus particles and all the groups were maintained in incubators at 35 °C and 50% RH to monitor pupal development. At 96 h post-inoculation (p.i.), all pupae of the groups were collected, then total RNA extraction was performed according to the manufacturer's instructions (TranGen, Beijing, China) and the extracts were stored at −80 °C until further use.

The quantification of the DWV titer in the samples was performed using real time qRT-PCR using the *TransScript*^®^ Green One-Step qRT-PCR SuperMix (TranGen, Beijing, China), and RT-qPCR reaction contained 75 ng RNA, 1 × *TransScript*^®^ Tip Green qPCR SuperMix, 1 × Passive Reference Dye, and 5 pmol of each primer: DWV-F1 and DWV-R1 (DWV-F1: 5′-TAGTGCTGGTTTTCCTTTGTC-3′; DWV-R1: 5′-CTGTGTGAGTAATTGAATCTC-3′) with Actin F1 and R1 (Actin-F1: 5′-CTTGGAATCGCAGATAGAATGC-3′; Actin-R1: 5′-AATTTTCATGGTGGATGGTGC-3′) as the reference gene. *Apis mellifera* β-actin, which is reported as a stable reference gene in the DWV infection, was used for normalization as described by [@ref-8]. The qPCR protocol for both DWV and β-actin reference gene was as follows: 45 °C for 5 min, 95 °C for 30 s, 40 cycles of 95 °C for 5 s, 54 °C for 30 s (DWV), 55 °C for 30 s (β-actin), and 72 °C for 20 s. The relative DWV titers of the pupae were assessed by calculating delta Ct values (ΔCt = Ct~(DWV)~ − Ct~(actin)~).

Statistical analysis
--------------------

All data are expressed as mean ± standard deviation. Statistical analyses were performed using GraphPad Prism 7.0 software (GrapPad, San Diego, CA, USA). Differences in the levels of antibodies, lymphocyte proliferation and cytokines among the various groups were evaluated using an independent samples *t*-test. *P* \< 0.05 was considered statistically significant.

Results
=======

Codon optimization of *VP1*, *VP2* and *VP3*
--------------------------------------------

After sequencing, the full lengths of *VP1*, *VP2* and *VP3* were 1248, 675 and 738 bp, encoding polypeptide of 416, 225 and 246 amino acid residues, respectively. Analysis of three structural protein genes revealed various rare codons, including CTT (Leu), CTA (Leu), CGA (Arg), AGA (Arg), AGG (Arg), GGA (Gly), ATA (Ile), CCC (Pro), TCA (Ser) and ACA (Thr) in *E. coli*. To obtain high expression level of the recombinant VP1, VP2 and VP3 proteins, *roVP1*, *roVP2* and *roVP3* were synthesized so as to replace the low-frequency-usage codons with high-frequency ones in *E. coli*. Results indicated that 71% (298/416; *roVP1*), 72% (162/225; *roVP2*) and 73% (180/246; *roVP3*) of the codons were optimized according the codon bias of the *E. coli* genome ([Table S1](#supp-3){ref-type="supplementary-material"}). The sequence alignment showed that codon-optimized *roVP1*, *roVP2* and *roVP3* shared 72.8%, 72.6% and 71.4% identity with wild-type *VP1*, *VP2* and *VP3*. Furthermore, the codon adaptation index (CAI) of the three genes increased from 0.19, 0.20 and 0.19 to 0.94, 0.95 and 0.94 ([Fig. S1](#supp-1){ref-type="supplementary-material"}), respectively; further, the GC content was also adjusted from 41%, 38% and 39% to 56%, 55% and 53%, respectively. The substitution of nucleotides did not alter their coding amino acid sequences.

Expression and purification of the recombinant proteins
-------------------------------------------------------

The recombinant plasmids containing *roVP1*, *roVP2* and *roVP3* were transformed into *E. coli* BL21 (DE3) and expressed under the induction of IPTG. The recombinant proteins roVP1 and roVP3 were expressed in a soluble form and purified from the supernatant. The recombinant protein roVP2 was expressed in an insoluble form, that is, as inclusion bodies, and was purified after solubilization in 6 M urea and by using Ni-affinity chromatography. SDS-PAGE analysis showed that the apparent molecular weights of the recombinant proteins were approximately 50.5 (*roVP1*), 29.1 (*roVP2*) and 32.6 kDa (*roVP3*), which was in accordance with their theoretical values ([Fig. 1](#fig-1){ref-type="fig"}). The optimized IPTG concentrations of expression were 0.5 (*roVP1*: [Fig. 1A](#fig-1){ref-type="fig"}), 0.1 (*roVP2*: [Fig. 1B](#fig-1){ref-type="fig"}), and 0.25 (*roVP3*: [Fig. 1C](#fig-1){ref-type="fig"}) mmol/L. After purification with Ni-affinity chromatography, the recombinant proteins were presented as a single band (*roVP1*: [Fig. 1A](#fig-1){ref-type="fig"}; *roVP2*: [Fig. 1B](#fig-1){ref-type="fig"}; *roVP3*: [Fig. 1C](#fig-1){ref-type="fig"}).

![Expression and purification of the recombinant proteins by SDS-PAGE analysis in *E. coli*.\
(A)--(C) represent the recombinant proteins r*oVP1*, *roVP2* and *roVP3*, respectively. Lane 1; protein weight marker. Lane 2--4; induced *E. coli* BL21 (DE3) of the corresponding plasmids after 6 h with 0.1 mM, 0.25 mM and 0.5 mM IPTG, respectively. Lane 5; uninduced *E. coli* BL21 (DE3) of the corresponding plasmids as control. Lane 6; purification of the corresponding recombinant proteins.](peerj-08-8750-g001){#fig-1}

Western blot analysis of the recombinant proteins
-------------------------------------------------

To determine the expression of the recombinant proteins, Western blot analysis was performed using mouse anti--His tag antibodies and anti-DWV polyclonal antibodies, but the recombinant proteins didn't combine with the negative control (the serum of healthy mice). The results showed that the single reaction bands corresponding to the bands in SDS-PAGE could be observed in the PVDF membrane, indicating the reactogenicity of the recombinant proteins *roVP1*, *roVP2* and *roVP3* to specific antibodies ([Figs. 2A](#fig-2){ref-type="fig"}--[2C](#fig-2){ref-type="fig"}; [Fig. S2](#supp-2){ref-type="supplementary-material"}).

![Western blot identification of the recombinant proteins with the anti-His tag antibody and mouse anti-DWV polyclonal antibody.\
(A)--(C) represent *roVP1*, *roVP2* and *roVP3*, respectively. Lane 1; anti-His tag antibody was used as primary antibody. Lane 2; mouse anti-DWV polyclonal antibodies as primary antibody. Lane 3; negative control (NC), the serum of healthy mice.](peerj-08-8750-g002){#fig-2}

Immune effect comparison for serum antibody titers
--------------------------------------------------

To evaluate the immunogenicity of the recombinant proteins, BALB/c mice were immunized with *roVP1*, *roVP2* or *roVP3* thrice at 2 week intervals and the total IgG antibody levels were measured using ELISA. As shown in [Fig. 3](#fig-3){ref-type="fig"} and [Table S2](#supp-4){ref-type="supplementary-material"}, after the first immunization, serum total IgG levels were higher in mice of the recombinant groups and group of the purified virus particles than in those of the control group (*P* \< 0.05). In addition, the mice that were inoculated with the purified virus particles induced higher levels of IgG antibodies than those of the other groups. After the booster immunization, the antibody levels in group *roVP3* were significantly higher than those in the *roVP2* and *roVP1* groups; the *roVP1* group induced the lowest immune response. At 2 weeks after the last immunization, high levels of IgG were detected in the three recombinant protein groups compared with those in the control PBS group (*P* \< 0.05). Although the difference between the *roVP3* and *roVP2* groups was insignificant (*P* \> 0.05), the antibody levels were higher in the *roVP3* group than in the *roVP2* group and both of them were significantly higher than those in the *roVP1* group (*P* \< 0.05). These results suggest that the three recombinant proteins had strong immunogenicity and that roVP3 effectively promoted the antibody levels induced in mice.

![Specific IgG antibodies in serum of the immunized mice.\
The OD~450~ value of total IgG were detected on 0, 2, 4 and 6 weeks post-vaccination. Data are expressed as the mean ± SD (*n* = 5) values. \*Significantly different compared with the control group (*P* \< 0.05). \*\*Significant differences between three groups immunized with recombinant proteins (*P* \< 0.05).](peerj-08-8750-g003){#fig-3}

Immune effect comparison for lymphocyte proliferation and cytokine secretion
----------------------------------------------------------------------------

To evaluate splenocyte proliferation in vitro, spleen cell suspensions from the mice of different groups were prepared at 2 weeks after the last immunization. Our data suggest that a significantly higher SI value was obtained from mice immunized with the recombinant protein groups and from the group of purified virus particles than from the control groups (*P* \< 0.05) ([Fig. 4](#fig-4){ref-type="fig"}; [Table S3](#supp-5){ref-type="supplementary-material"}). Moreover, the *roVP2* group exhibited the highest level of lymphocyte proliferation (SI = 1.96 ± 0.18), which was insignificantly different from that in the *roVP1* and *roVP3* groups; further, lymphocyte proliferation in the *roVP3* group (SI = 1.79 ± 0.10) was higher than that in the *roVP1* group (SI = 1.72 ± 0.12). These results indicate that the recombinant proteins successfully stimulated the mice to promote lymphocyte proliferation.

![Lymphocyte proliferation responses of immunized mice.\
The values of the stimulation index (SI) were calculated at 6 weeks post-vaccination. Data are expressed as the mean ± SD (*n* = 5) values. \*Significantly different than the control group (*P* \< 0.05).](peerj-08-8750-g004){#fig-4}

The levels of serum IL-2, IL-4, IL-10 and IFN-γ in each group are shown in [Fig. 5](#fig-5){ref-type="fig"} and [Table S4](#supp-6){ref-type="supplementary-material"}. Compared with the PBS control group, the IL-2, IL-4, IL-10 and IFN-γ concentrations in the recombinant protein groups were significantly higher (*P* \< 0.05) at 2 weeks after the last immunization. Among the recombinant protein groups, the IL-2 and IFN-γ levels were significantly higher in the *roVP2* group than in the *roVP1* and *roVP3* groups (*P* \< 0.05) and the mice immunized with *roVP3* showed significantly higher levels of IL-4 (*P* \< 0.05). However, the level of IL-10 was not statistically significantly different in the *roVP1*, *roVP2* and *roVP3* groups (*P* \> 0.05). These results show that immunization with the recombinant proteins induced T-cells to secret multiple cytokines.

![Cytokine response in sera of immunized mice.\
(A)--(D) represent the levels of cytokines IL-2, IL-4, IL-10 and IFN-γ by ELISA, respectively. Data are expressed as the mean ± SD (*n* = 5) values. \*Significantly different compared with the control group (*P* \< 0.05). \*\*Significant differences between three groups immunized with recombinant proteins (*P* \< 0.05).](peerj-08-8750-g005){#fig-5}

The result of Challenge test in the honeybee pupae
--------------------------------------------------

The aim of challenge test was to evaluate whether antisera against DWV recombinant structural protein could neutralize virus in honeybee pupae. As seen in [Fig. 6](#fig-6){ref-type="fig"} and [Table S5](#supp-7){ref-type="supplementary-material"}, the DWV levels in the group infected with only virus were significantly higher than other groups, indicating that DWV could massively replicate in the pupae at the 96 h. At the same time, the DWV level in the pupae of the five-antisera-only group was significantly lower than in the pupae of any other treatment groups. From the analysis of qRT-PCR data, DWV was undetectable by qRT-PCR in the group injected with five antisera. Compared with the group injected virus particles, we detected a markedly lower relative normalized virus titer in the anti-*roVP*1/2/3-antisera groups and positive control group (anti-DWV-antisera); all of them significantly differed from the virus particles group (*P* \< 0.05), suggesting that anti-*roVP*1/2/3-antisera or anti-DWV-antisera could neutralize DWV virus particles. Moreover, the anti-DWV-antisera group showed the lowest virus titer in all groups ([Fig. 6](#fig-6){ref-type="fig"}; [Table S5](#supp-7){ref-type="supplementary-material"}). Among anti-*roVP*1/2/3-antisera groups, the relative virus titer of *roVP3* group was the lowest and it significantly differed from that in the *roVP1* groups (*P* \< 0.05) ([Fig. 6](#fig-6){ref-type="fig"}; [Table S5](#supp-7){ref-type="supplementary-material"}). These indicated that specific antibody, which was produced in the mice immunized with the recombinant proteins, could neutralize DWV and reduce the virus titer in the pupae.

![Relative normalized DWV of the honeybee pupae.\
The quantification of DWV titer in the samples was performed by the real time qRT-PCR, and the relative normalized DWV titer was determined as the DWV titer after normalization with the reference gene Actin and the relative DWV titers of the pupae were assessed by calculating delta Ct values (ΔCt = Ct~(DWV)~ − Ct~(actin)~). \*Significantly different compared with the virus-only group (*P* \< 0.05). \*\*Significant differences between three groups immunized with recombinant proteins (*P* \< 0.05).](peerj-08-8750-g006){#fig-6}

Discussion
==========

DWV is one of the most prevalent and pathogenic viruses affecting honey bee in the world and it has been directly linked to colony collapse disorder ([@ref-2]; [@ref-21]). At present, research of DWV is being focused on the isolation and sequence analysis of the strains, the epidemiological investigation of the interaction with *Varroa destructor*, and the establishment of a rapid detection method ([@ref-4]; [@ref-22]; [@ref-39]; [@ref-45]). However, research on therapeutic drugs against DWV is still rare. Egg yolk antibodies known as immunoglobulin Y (IgY) have been widely utilized in the prevention and control of epidemic diseases associated with *Acinetobacter baumannii*, *Vibrio splendidus*, the Dengue virus, noroviruses, rotaviruses and duck adenovirus 3 ([@ref-13]; [@ref-16]; [@ref-20]; [@ref-26]; [@ref-44]). Moreover, [@ref-38] reported that specific IgY could be obtained from hens immunized with an inactivated Chinese Sacbrood virus (CSBV) vaccine, which has the ability to neutralize CSBV. Therefore, we should be able to develop novel therapeutic drugs against DWV using this strategy. However, owing to lack of an efficient cell culture system and limited animal models for DWVs, we were unable to obtain large amounts of the viral protein to perform further research in this direction. At the same time, the immunogenicity and antigenic differences among the DWV structural proteins remain unclear. In this study, we successfully produced the recombinant DWV proteins *roVP1*, *roVP2* and *roVP3* via expression in *E. coli* to evaluate their immunogenicity and Western blot analysis of the recombinant proteins conducted using anti-His monoclonal antibodies and anti-DWV polyclonal antibodies confirmed the identity of the target proteins, indicating that the DWV structural protein genes can be expressed in a prokaryotic system.

Comparing the codon usage in *E. coli*, we found many rare codons in the wild DWV structural protein genes and CAI values of the three target genes were only approximately 0.2; this likely results in lower expression yields---even expression failure---in *E. coli*. Codon optimization can improve protein production via optimization of translation elongation and previous reports have shown that a codon-optimization strategy can improve the expression level of genes in many species ([@ref-9]; [@ref-18]; [@ref-33]; [@ref-37]). In this study, the rare codons of DWV *VP1*, *VP2* and *VP3* were replaced with the most highly preferred codons and the GC content was changed to approximately 70%. In addition, the AT-rich fragment was removed to avoid premature translation termination. After optimization, the CAI value of the three genes reached approximately 0.95. To avoid the impact of tag proteins on the spatial conformation of the recombinant protein, we selected pET28a (+) as the expression vector because the molecular weight of the His--tag protein is only approximately 0.8 kDa. SDS-PAGE showed that optimized *roVP1*, *roVP2* and *roVP3* were efficiently expressed in *E. coli*. Prokaryotic expression offers many advantages, such as simple manipulation, relatively low capital costs and fitting mass production ([@ref-28]), and serves as a convenient method for obtaining large numbers of recombinant proteins; however, protein sequences of VP1, VP2 and VP3 probably exist as potential glycosilation sites as per online software analysis (<http://www.cbs.dtu.dk/services/NetNGlyc/>) and the influence of potential glycosilation sites on the immunogenicity requires further research.

Research has indicated that structural proteins of the virus not only play an important role in viral invasion and replication but also have excellent immunogenicity and that they are frequently selected as candidates for the development of therapeutic antibodies ([@ref-19]; [@ref-27]; [@ref-36]; [@ref-41]). Compared with vertebrate immune systems, honey bee immune pathways lack acquired immunity ([@ref-6]) and cannot directly generate specific antibodies in response to an antigen. We therefore hope to prepare the antibody against DWV by the mammal in the present study and humoral immunity is thought to be critical to evaluate the immunogenicity of the three recombinant proteins. Our results showed that among the three recombinant proteins, roVP3 induced the highest levels of specific IgG in the serum. IL-2 and INF-γ are mainly secreted by Th1 cells, which promote cellular immune responses and IL-4 and IL-10 are mainly secreted by Th2 cells, which promote humoral immune responses ([@ref-41]; [@ref-46]). Comparing SI values and and cytokines, we speculate that *roVP2* has a strong effect on cellular immune responses and that *roVP3* can induce a strong humoral immune response in the mice, although all the three recombinant proteins could stimulate cellular and humoral immune responses.

In the challenge test, all the anti-roVP1/2/3-antisera could confer to the pupae protection against DWV, which indicated that antisera against recombinant protein of the mice possess the ability of neutralizing virus. Although co-injection with anti-DWV or roVP1/2/3-antisera could reduce DW levels, whether they prevent development of DWV infection need further research. In the previous research, the C-terminal extension of VP3 protein folds into a globular protruding (P) domain, exposed on the surface of the virion, which contains five Asp-His-Ser residues and the P domain may participate in receptor-binding or provide the protease, lipase, or esterase activity required for entry of the virus into a host cell ([@ref-35]), and anti-*roVP3*-antisera show the most superior viru-neutralizing ability in challenge test; thus, we speculated that anti-*roVP3*-antisera inhibits virus entry into target cells by the prevention of conformational changes within P domain or the inhibition of receptor binding. These results of the challenge test provide a new idea for development of a treatment strategy against DWV.

Conclusion
==========

In summary, the present study has shown for the first time that the DWV structural proteins *VP1*, *VP2* and *VP3* can be efficiently expressed in *E. coli* using a codon-optimization strategy. Based on the results of mice immunization experiments and challenge test, we found that the recombinant proteins *roVP3* and *roVP2* have excellent immunogenicity in mice. After the virus were incubated with the specific antibodies against DWV capsid proteins, virus copies from challenged pupae reduced significantly on quantitative real-time RT-PCR detection in the challenge test, which indicated that the specific antibodies against DWV capsid proteins could neutralize DWV. Thus, they are promising candidate immunogens for the development of therapeutic antibodies. Our research provides a novel pathway for exploiting anti-DWV biological drugs and may aid further research concerning the effects of DWV on honey bees.
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